Table 7 Cox proportional hazard regression analysis evaluating risk of cardiovascular mortality regarding rs1478604 of TSP-1 in the study population divided in the total population, and into the two genders

Age

1.17

1.10–1.25

< 0.0001

1.20

1.07–1.34

0.002

1.20

1.10–1.30

< 0.0001

IHD

1.23

0.74–2.03

0.42

1.13

0.44–2.89

0.80

1.05

0.55–2.01

0.88

Hypertension

1.17

0.71–1.93

0.53

1.85

0.72–4.71

0.20

1.04

0.58–1.89

0.89

Diabetes

1.25

0.82–1.93

0.30

1.90

0.86–4.18

0.11

0.87

0.50–1.50

0.61

AECI/ARB

1.00

0.62–1.61

0.99

0.73

0.32–1.66

0.45

1.30

0.72–2.36

0.39

Beta blockers

0.77

0.48–1.24

0.28

0.76

0.35–1.65

0.48

0.78

0.42–1.46

0.43

Atrial fibr.

2.23

1.30–3.86

0.004

4.66

1.69–12.83

0.003

1.71

0.85–3.45

0.13

Hb < 120 g/L

1.42

0.82–2.49

0.21

2.52

1.07–5.94

0.04

1.03

0.44–2.40

0.94

EF < 40%

1.79

0.96–3.33

0.07

3.57

1.14–11.20

0.03

1.41

0.63–3.16

0.40

TSP-1 rs1478604, T/T

1.62

1.03–2.53

0.04

3.18

1.35–7.50

0.008

1.18

0.68–2.05

0.56